Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Nutriband ( (NTRB) ).
Nutriband Inc. announced the signing of an addendum to its agreement with Kindeva Drug Delivery, formalizing their exclusive partnership and long-term commitment for the development of Aversa™ Fentanyl. This partnership aims to leverage Nutriband’s AVERSA™ abuse-deterrent technology to create the world’s first abuse-deterrent opioid patch, potentially reaching peak annual US sales of $80 million to $200 million.
More about Nutriband
Nutriband Inc. is involved in the development of prescription transdermal pharmaceutical products, with a focus on incorporating aversive agents into transdermal patches to deter the misuse of drugs, such as opioids and stimulants.
YTD Price Performance: 56.48%
Average Trading Volume: 196,964
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $79.08M
Find detailed analytics on NTRB stock on TipRanks’ Stock Analysis page.
